This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
There is now a drug on the U.S. market, approved this week, called Bkemv. I’m not kidding. I wish I were.
I’m flying to Chicago today for the ASCO meeting. I’ll be posting cancer-related dispatches all weekend, in case you need something to read on the beach.
Now, let’s disaggregate those sentiment scores by investor type. More institutional-type investors, in red, have become more bullish since our last survey, with nearly half
Hyperkalemia in type 2 diabetes occurred less often with GLP-1 receptor agonists in routine care than dipeptidyl peptidase-4 (DPP-4) inhibitors, a large observational study in
The BIOSECURE Act could impact more than 120 US biopharmaceutical drugs in development by companies partnered with Chinese contract development and manufacturing organisations (CDMOs) and
